CVSCVS HEALTH Corp

NYSE cvshealth.com


$ 56.30 $ -11.40 (-16.84 %)    

Wednesday, 01-May-2024 15:59:59 EDT
QQQ $ 422.58 $ -3.07 (-0.72 %)
DIA $ 378.81 $ 0.76 (0.2 %)
SPY $ 500.35 $ -1.63 (-0.32 %)
TLT $ 88.50 $ 0.65 (0.74 %)
GLD $ 213.80 $ 1.92 (0.91 %)
$ 56.31
$ 59.82
$ 56.30 x 200
$ 80.00 x 100
$ 54.00 - $ 59.82
$ 54.00 - $ 81.71
65,340,563
na
71.34B
$ 0.78
$ 9.75
TBD
na
na ($ 0.05)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-01-2024 03-31-2024 10-Q
2 02-07-2024 12-31-2023 10-K
3 11-01-2023 09-30-2023 10-Q
4 08-02-2023 06-30-2023 10-Q
5 05-03-2023 03-31-2023 10-Q
6 02-08-2023 12-31-2022 10-K
7 11-02-2022 09-30-2022 10-Q
8 08-03-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 02-09-2022 12-31-2021 10-K
11 11-03-2021 09-30-2021 10-Q
12 08-04-2021 06-30-2021 10-Q
13 05-04-2021 03-31-2021 10-Q
14 02-16-2021 12-31-2020 10-K
15 11-06-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-06-2020 03-31-2020 10-Q
18 02-18-2020 12-31-2019 10-K
19 11-06-2019 09-30-2019 10-Q
20 08-07-2019 06-30-2019 10-Q
21 05-01-2019 03-31-2019 10-Q
22 02-28-2019 12-31-2018 10-K
23 11-06-2018 09-30-2018 10-Q
24 08-08-2018 06-30-2018 10-Q
25 05-02-2018 03-31-2018 10-Q
26 02-14-2018 12-31-2017 10-K
27 11-06-2017 09-30-2017 10-Q
28 08-08-2017 06-30-2017 10-Q
29 05-02-2017 03-31-2017 10-Q
30 02-09-2017 12-31-2016 10-K
31 11-08-2016 09-30-2016 10-Q
32 08-02-2016 06-30-2016 10-Q
33 05-03-2016 03-31-2016 10-Q
34 02-09-2016 12-31-2015 10-K
35 10-30-2015 09-30-2015 10-Q
36 08-04-2015 06-30-2015 10-Q
37 05-01-2015 03-31-2015 10-Q
38 02-10-2015 12-31-2014 10-K
39 11-04-2014 09-30-2014 10-Q
40 08-05-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 leerink-partners-downgrades-cvs-health-to-market-perform-announces-60-price-target

Leerink Partners analyst Michael Cherny downgrades CVS Health (NYSE:CVS) from Outperform to Market Perform and announces $60...

 cantor-fitzgerald-downgrades-cvs-health-to-neutral-lowers-price-target-to-58

Cantor Fitzgerald analyst Sarah James downgrades CVS Health (NYSE:CVS) from Overweight to Neutral and lowers the price targe...

 rising-cost-for-health-insurers-bites-cvs-healths-q1-profit-stock-tanks

CVS Health Q1 sales of $88.4 billion, up 3.7% Y/Y. Adjusted EPS at $1.31, down from $2.20. Health Care Benefits segment sees st...

 wall-street-set-to-open-lower-after-amd-earnings-disappoint-as-traders-look-to-feds-powell-for-relief-why-this-analyst-sees-incoming-summer-rally

A negative sentiment might linger on Wall Street on Wednesday, as evidenced by stock futures, after Advanced Micro Devices, Inc...

 cvs-health-cuts-2024-adjusted-eps-guidance-to-at-least-700-from-at-least-830-versus-consensus-of-827

The Company's guidance revision reflects the assumption that the majority of utilization pressure observed in the Health Ca...

 cvs-health-q1-2024-adj-eps-131-misses-169-estimate-sales-88437b-miss-89209b-estimate

CVS Health (NYSE:CVS) reported quarterly earnings of $1.31 per share which missed the analyst consensus estimate of $1.69 by 22...

 will-earnings-cheer-continue-to-buoy-markets-apple-amazon-pfizer-coinbase-lead-flurry-of-q1-reports-this-week

With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and...

 arthritis-patients---cignas-evernorth-to-offer-humira-biosimilar-at-no-out-of-pocket-cost

Evernorth Health Services' initiative to offer Humira biosimilar with $0 out-of-pocket costs for patients. Save an average ...

 pharmacy-guild-says-pharmacy-professionals-at-cvs-omnicare-in-las-vegas-vote-overwhelmingly-to-form-union-with-the-pharmacy-guild

- Reuters

 freeport-mcmoran-applovin-and-a-major-healthcare-stock-on-cnbcs-final-trades

On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said AppLovin Corporation (NASDAQ...

 see-how-floridas-much-awaited-medicaid-re-procurement-awards-impact-centene-humana-molina

Florida announces Medicaid contract awards to Centene, Elevance Health, and Humana, sidelining UnitedHealth, CVS Health, and Mo...

 cantor-fitzgerald-reiterates-overweight-on-cvs-health-maintains-87-price-target

Cantor Fitzgerald analyst Sarah James reiterates CVS Health (NYSE:CVS) with a Overweight and maintains $87 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION